Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.32 Billion DKK | -16.3% |
| 2022 | 6.35 Billion DKK | 110.64% |
| 2021 | 3.01 Billion DKK | -52.19% |
| 2020 | 6.31 Billion DKK | 139.31% |
| 2019 | 2.63 Billion DKK | 91.12% |
| 2018 | 1.38 Billion DKK | 2.69% |
| 2017 | 1.34 Billion DKK | 27.67% |
| 2016 | 1.05 Billion DKK | 44.15% |
| 2015 | 730.37 Million DKK | 175.43% |
| 2014 | 265.17 Million DKK | 282.91% |
| 2013 | 69.25 Million DKK | 159.35% |
| 2012 | -116.67 Million DKK | 53.22% |
| 2011 | -249.42 Million DKK | -55.22% |
| 2010 | -160.68 Million DKK | 67.74% |
| 2009 | -498.03 Million DKK | 42.75% |
| 2008 | -869.99 Million DKK | -99.02% |
| 2007 | -437.13 Million DKK | 7.43% |
| 2006 | -472.21 Million DKK | -10.35% |
| 2005 | -427.92 Million DKK | -196.97% |
| 2004 | 441.27 Million DKK | 228.95% |
| 2003 | -342.2 Million DKK | 29.16% |
| 2002 | -483.08 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.81 Billion DKK | 104.74% |
| 2024 Q1 | 801 Million DKK | -52.04% |
| 2023 Q3 | 1.71 Billion DKK | 14.7% |
| 2023 Q1 | 437 Million DKK | -83.6% |
| 2023 FY | 5.32 Billion DKK | -16.3% |
| 2023 Q2 | 1.49 Billion DKK | 242.56% |
| 2023 Q4 | 1.67 Billion DKK | -2.74% |
| 2022 FY | 6.35 Billion DKK | 110.64% |
| 2022 Q2 | 1.24 Billion DKK | 142.61% |
| 2022 Q1 | 514 Million DKK | -36.46% |
| 2022 Q3 | 1.93 Billion DKK | 54.85% |
| 2022 Q4 | 2.66 Billion DKK | 38.01% |
| 2021 FY | 3.01 Billion DKK | -52.19% |
| 2021 Q4 | 809 Million DKK | -9.1% |
| 2021 Q3 | 890 Million DKK | 13.09% |
| 2021 Q2 | 787 Million DKK | 47.93% |
| 2021 Q1 | 532 Million DKK | -40.02% |
| 2020 Q3 | 858 Million DKK | -80.92% |
| 2020 FY | 6.31 Billion DKK | 139.31% |
| 2020 Q4 | 887 Million DKK | 3.38% |
| 2020 Q2 | 4.49 Billion DKK | 6233.8% |
| 2020 Q1 | 71 Million DKK | -96.74% |
| 2019 Q3 | -398.42 Million DKK | -390.47% |
| 2019 Q2 | 137.16 Million DKK | 629.11% |
| 2019 Q1 | -25.92 Million DKK | -103.6% |
| 2019 Q4 | 2.17 Billion DKK | 646.16% |
| 2019 FY | 2.63 Billion DKK | 91.12% |
| 2018 Q2 | 135.04 Million DKK | -58.33% |
| 2018 Q1 | 324.04 Million DKK | -53.93% |
| 2018 FY | 1.38 Billion DKK | 2.69% |
| 2018 Q4 | 721.02 Million DKK | 260.2% |
| 2018 Q3 | 200.17 Million DKK | 48.23% |
| 2017 FY | 1.34 Billion DKK | 27.67% |
| 2017 Q4 | 703.38 Million DKK | 1106.49% |
| 2017 Q2 | 536.41 Million DKK | 1064.35% |
| 2017 Q3 | 58.3 Million DKK | -89.13% |
| 2017 Q1 | 46.07 Million DKK | -93.49% |
| 2016 Q3 | 186.83 Million DKK | 31.78% |
| 2016 FY | 1.05 Billion DKK | 44.15% |
| 2016 Q4 | 707.87 Million DKK | 278.88% |
| 2016 Q1 | 16.33 Million DKK | -95.65% |
| 2016 Q2 | 141.78 Million DKK | 767.75% |
| 2015 Q1 | 172.94 Million DKK | 182.52% |
| 2015 Q3 | 142.67 Million DKK | 261.97% |
| 2015 Q2 | 39.41 Million DKK | -77.21% |
| 2015 Q4 | 375.34 Million DKK | 163.07% |
| 2015 FY | 730.37 Million DKK | 175.43% |
| 2014 Q3 | 139.32 Million DKK | 539.37% |
| 2014 FY | 265.17 Million DKK | 282.91% |
| 2014 Q4 | 61.21 Million DKK | -56.06% |
| 2014 Q2 | -31.71 Million DKK | -132.91% |
| 2014 Q1 | 96.35 Million DKK | 80.71% |
| 2013 Q3 | 4.69 Million DKK | 126.3% |
| 2013 FY | 69.25 Million DKK | 159.35% |
| 2013 Q2 | -17.86 Million DKK | -161.39% |
| 2013 Q1 | 29.1 Million DKK | 468.62% |
| 2013 Q4 | 53.31 Million DKK | 1034.62% |
| 2012 Q1 | -44.14 Million DKK | 31.39% |
| 2012 Q4 | -7.89 Million DKK | 71.03% |
| 2012 FY | -116.67 Million DKK | 53.22% |
| 2012 Q2 | -37.38 Million DKK | 15.33% |
| 2012 Q3 | -27.25 Million DKK | 27.08% |
| 2011 Q1 | -61.73 Million DKK | 29.3% |
| 2011 Q3 | -57.91 Million DKK | 11.5% |
| 2011 Q2 | -65.43 Million DKK | -6.0% |
| 2011 FY | -249.42 Million DKK | -55.22% |
| 2011 Q4 | -64.34 Million DKK | -11.11% |
| 2010 Q4 | -87.31 Million DKK | -152.31% |
| 2010 Q2 | -93.8 Million DKK | 35.97% |
| 2010 Q1 | -146.5 Million DKK | -7.09% |
| 2010 FY | -160.68 Million DKK | 67.74% |
| 2010 Q3 | 166.93 Million DKK | 277.96% |
| 2009 Q1 | -36.65 Million DKK | 0.0% |
| 2009 FY | -498.03 Million DKK | 42.75% |
| 2009 Q3 | -148.24 Million DKK | 15.92% |
| 2009 Q4 | -136.8 Million DKK | 7.71% |
| 2009 Q2 | -176.32 Million DKK | -380.98% |
| 2008 FY | -869.99 Million DKK | -99.02% |
| 2007 FY | -437.13 Million DKK | 7.43% |
| 2006 FY | -472.21 Million DKK | -10.35% |
| 2005 FY | -427.92 Million DKK | -196.97% |
| 2004 FY | 441.27 Million DKK | 228.95% |
| 2003 FY | -342.2 Million DKK | 29.16% |
| 2002 FY | -483.08 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 7512.309% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -108164.59% |
| SQZ Biotechnologies Company | -75.82 Million USD | 7117.474% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 29914.535% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -6400.765% |
| Mesoblast Limited | -84.14 Million USD | 6423.458% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 346508.22% |
| Genus plc | 6.4 Million USD | -83040.625% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -54516.601% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 571402.798% |
| Marizyme, Inc. | -34.08 Million USD | 15710.278% |
| ContraFect Corporation | -56.88 Million USD | 9453.302% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 63824.551% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 116923.712% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 379631.68% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 186768.547% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 193531.895% |
| MultiCell Technologies, Inc. | -722.81 USD | 736154829.459% |
| Accustem Sciences Inc. | -3.74 Million USD | 142128.962% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 9120.173% |
| EV Biologics, Inc. | -483.06 Thousand USD | 1101614.919% |
| Q BioMed Inc. | -3.44 Million USD | 154528.12% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -150210.734% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1365964.928% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 202610.198% |
| Biomind Labs Inc. | -1 Million USD | 527138.846% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 109147.075% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 80138.929% |
| Skye Bioscience, Inc. | -13.67 Million USD | 39019.528% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 267960.873% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 17765190.812% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 105581.573% |
| IMV Inc. | -38.67 Million USD | 13859.482% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 33629.226% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 275427.148% |
| GB Sciences, Inc. | -1.42 Million USD | 374684.04% |
| Alpha Cognition Inc. | -9.7 Million USD | 54924.013% |
| HST Global, Inc. | -140.9 Thousand USD | 3776349.583% |
| CSL Limited | 3.7 Billion USD | -43.733% |
| Halberd Corporation | -75.05 Thousand USD | 7090040.04% |
| Enzolytics Inc. | -2.14 Million USD | 247726.582% |
| Resverlogix Corp. | -12.74 Million USD | 41836.607% |
| Affymax, Inc. | -15.04 Million USD | 35464.881% |
| SYBLEU INC | -149.18 Thousand USD | 3566932.015% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 168046.333% |
| argenx SE | -425.04 Million USD | 1351.856% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 9686.006% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 509774.33% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 337009.688% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 156371.155% |
| AVAX Technologies, Inc. | 6.69 Million USD | -79402.397% |
| Zenith Capital Corp. | -8.94 Million USD | 59599.05% |
| Genscript Biotech Corporation | -415.79 Million USD | 1379.729% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 30543696.808% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 216813.361% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 3102551.327% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 9779.41% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 183503.705% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 540822.908% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 285504.721% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 423746.497% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 265518.702% |
| BioStem Technologies, Inc. | -7.77 Million USD | 68502.381% |
| ONE Bio Corp. | 13.68 Million USD | -38791.795% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 2932022.748% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 398548.141% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 473117.301% |
| Agentix Corp. | -1.37 Million USD | 387996.973% |
| LadRx Corporation | -3.82 Million USD | 139261.1% |
| Cell Source, Inc. | -4.32 Million USD | 123119.06% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1280790.48% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 774683.303% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 774683.303% |
| NovAccess Global Inc. | -2.46 Million USD | 215808.054% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 182360.732% |
| Itoco Inc. | -919.14 Thousand USD | 579010.721% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 125642.243% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 475613.852% |
| Kadimastem Ltd | -3.04 Million USD | 175118.502% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 2033142.189% |
| CytoDyn Inc. | -18.05 Million USD | 29566.165% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 21140346.325% |
| Mobile Lads Corp. | -554.55 Thousand USD | 959616.725% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 2417879.151% |
| Qrons Inc. | -643.67 Thousand USD | 826756.848% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 942331.855% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 238722.813% |
| Rebus Holdings, Inc. | -664 Thousand USD | 801455.422% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 293054.986% |
| International Stem Cell Corporation | -663 Thousand USD | 802664.103% |
| Bioxytran, Inc. | -3.82 Million USD | 139387.834% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 10108382.675% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 26160375.32% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 14772.145% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 328962.794% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 723224.07% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 171138.251% |
| Neutra Corp. | -229.48 Thousand USD | 2318759.962% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 30438.104% |
| PureTech Health plc | -146.19 Million USD | 3739.56% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 24859.063% |
| IXICO plc | -1.43 Million USD | 370385.317% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 56163.639% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 4468.422% |
| CSL Limited | 3.81 Billion USD | -39.586% |
| Cellectis S.A. | -108.85 Million USD | 4988.048% |